Crossmark

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

Published Online: 2018-08-13

Published Print: 2018-12

Authors

Denard, Bray

Jiang, Sharon

Peng, Yan

Ye, Jin http://orcid.org/0000-0002-3179-4777
Funding

Funding for this research was provided by:

National Institute of General Medical Sciences (GM-116106)

National Heart, Lung, and Blood Institute (HL-20948)

Welch Foundation (I-1832)
License Information

Text and Data Mining valid from 2018-08-13

Version of Record valid from 2018-08-13
More Information

Article History

Received: 14 September 2017

Accepted: 3 August 2018

First Online: 13 August 2018

Ethics approval and consent to participate

: Informed consent to participate in the study was obtained from participants. The use of the patient materials and information has been approved by the University of Texas Southwestern Medical Center Institutional Review Board (IRB# STU032011-117).

: Not Applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current